Nimbus-T Global | Secure Identity Management
  • Home
  • Nimbus-Key
    • Secure Identity
    • Smart directory
    • Secure Messaging
    • Telehealth
    • Blockchain
  • Cyber Guide
  • About
    • Contact Us
  • Register
  • Blog
Select Page
Can a cancer treatment work on COVID-19?

Can a cancer treatment work on COVID-19?

by Duke-NUS | Apr 27, 2020 | news, Covid-19 / Coronavirus, Oncology

Researchers are exploring engineering specific virus-targeting receptors onto a patient’s own immune cells as a way to fight infectious diseases, including COVID-19.

Grail validation data show highly accurate detection of cancers, tissues of origin

Grail validation data show highly accurate detection of cancers, tissues of origin

by Alaric DeArment | Oct 14, 2019 | Cybersecurity, news, Oncology

A test in development for early detection of cancers was able to pick up a dozen of the deadliest cancer types at stages I-IV with a high degree of accuracy while also determining where the tumor was located, according to validation data announced Monday.

Celgene invests $75M in cell therapy company Immatics as part of T-cell receptor partnership

Celgene invests $75M in cell therapy company Immatics as part of T-cell receptor partnership

by Alaric DeArment | Sep 5, 2019 | Biopharma, Healthcare Innovation

A large biotech company is pouring tens of millions of dollars into a German firm under a partnership to develop cell therapies in oncology.

Roche drug is third to win biomarker-driven cancer approval from FDA

Roche drug is third to win biomarker-driven cancer approval from FDA

by Alaric DeArment | Aug 23, 2019 | Biopharma

Another drug designed to treat cancer patients based on a genetic driver rather than where tumors occur in the body has received approval from the Food and Drug Administration.

Kite Pharma founder’s venture capital firm closes new $600M fund

Kite Pharma founder’s venture capital firm closes new $600M fund

by Alaric DeArment | Aug 6, 2019 | Biopharma, Oncology

Boston-based Vida Ventures said Thursday that it had closed its Vida Ventures II, or Vida II fund, raising $600 million.

Exact Sciences buys fellow oncology diagnostics company Genomic Health for $2.8B

Exact Sciences buys fellow oncology diagnostics company Genomic Health for $2.8B

by Kevin Truong | Aug 5, 2019 | Biopharma

Exact Sciences has agreed to purchase Genomic Health in a $2.8 billion cash-and-stock deal to create a powerhouse in the oncology diagnostics industry.

« Older Entries

Blog Stats

  • 30,434 hits

Recent Posts

  • Rob Joyce Appointed Director of Cybersecurity at NSA
  • NSA Publishes Cybersecurity Year in Review Report
  • Passwordless tech startup Beyond Identity raises $75 million
  • Vulnerability Exposes F5 BIG-IP Systems to Remote DoS Attacks
  • Google closes $2.1B acquisition of Fitbit as Justice Department probe continues

Categories

  • AI
  • Banking
  • Big Data
  • Biopharma
  • Blockchain
  • Clinical Trials
  • Concierge Medicine
  • Covid-19 / Coronavirus
  • Cryptocurrency
  • Cybersecurity
  • Digital Health
  • EMR
  • Encryption
  • Fraud
  • Funding
  • Genomics
  • Hacked
  • Health Insurance
  • Healthcare Costs
  • Healthcare Innovation
  • Hospital News
  • Hospital Security
  • Identity Management
  • Investment Opportunity
  • news
  • Oncology
  • Patient Identity
  • Precision Medicine
  • Ransomware
  • Telehealth
  • Venture Capital

Nimbus-T Global inc

5570 Baldwin Way
Pleasanton, CA 94588

Copyright 2020

Translation


 Edit Translation

Blog Stats

  • 30,434 hits
Powered by Nimbus-T Global Inc. © 2020 All Rights Reserved
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok